- Conditions
- Moderate to Severe Ulcerative Colitis
- Interventions
- Double-Blind 0.2mg CBP-307, Double-Blind Placebo, Open-label CBP-307, Double-Blind 0.1mg CBP-307
- Drug
- Lead sponsor
- Connect Biopharm LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Mission Hills, California • Hialeah, Florida + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1321–1344
of 33,598
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Phenylketonuria
- Interventions
- AG-181
- Drug
- Lead sponsor
- Agios Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Pittsburgh, Pennsylvania • Dallas, Texas
- Conditions
- Tobacco Use Disorder
- Interventions
- Progesterone, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 42 Years · Female only
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Acute Adenoviral Conjunctivitis
- Interventions
- FST-100, FST-100 (Component #1), FST-100 Vehicle
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Cancer, Non-Small Cell Lung Cancer
- Interventions
- XL765 (SAR245409), erlotinib
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Healthy Volunteers, Pneumococcal Disease
- Interventions
- ASP3772, PCV13
- Biological
- Lead sponsor
- Affinivax, Inc.
- Industry
- Eligibility
- 12 Months to 15 Months
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 17
- States / cities
- Bryant, Arkansas • Jonesboro, Arkansas • Anaheim, California + 14 more
- Conditions
- Delayed Graft Function, DGF, Kidney Transplant
- Interventions
- Ravulizumab, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 26 more
- Conditions
- Osteoarthritis
- Interventions
- AGG-523 (Aggrecanase Inhibitor)
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Newton, Massachusetts • Winchester, Massachusetts + 1 more
- Conditions
- Lung Cancer, Breast Cancer
- Interventions
- BMS-986507, Osimertinib, Pembrolizumab, Nivolumab, Pumitamig
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Miami, Florida • Iowa City, Iowa + 9 more
- Conditions
- Schizophrenia
- Interventions
- GXV813, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 7
- States / cities
- Bentonville, Arkansas • Pico Rivera, California • Miami, Florida + 3 more
- Conditions
- Alzheimer's Disease, Healthy Non-elderly and Elderly Adults
- Interventions
- AL001, Placebo
- Drug · Other
- Lead sponsor
- Alzamend Neuro, Inc.
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Decatur, Georgia
- Conditions
- Myelodysplastic Syndrome (MDS)
- Interventions
- ON 01910 Na
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chemotherapy-Induced Thrombocytopenia
- Interventions
- ONO-7746
- Drug
- Lead sponsor
- Ono Pharma USA Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 3
- States / cities
- Fort Collins, Colorado • Augusta, Georgia • Ames, Iowa
- Conditions
- Advanced Solid Tumors, HR+ Breast Cancer, CCNE1 Amplification, HER2-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Gastric Cancer, Esophageal Adenocarcinoma, Carcinosarcoma
- Interventions
- BLU-222, Carboplatin, Ribociclib, Fulvestrant
- Drug
- Lead sponsor
- Blueprint Medicines Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • San Francisco, California • Stanford, California + 13 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- MB07803, Placebo
- Drug
- Lead sponsor
- Ligand Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 25
- States / cities
- Los Angeles, California • Walnut Creek, California • Miami, Florida + 20 more
- Conditions
- Advanced EGFR Positive Solid Tumor
- Interventions
- ZZ06
- Biological
- Lead sponsor
- Changchun Intellicrown Pharmaceutical Co. LTD
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Fairway, Kansas • The Bronx, New York
- Conditions
- Obesity, Overweight
- Interventions
- NNC0487-0111, Placebo (NNC0487-0111)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- San Antonio, Texas
- Conditions
- Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
- Interventions
- Bimekizumab, Ustekinumab, Placebo
- Drug · Other
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 567 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Bakersfield, California • San Diego, California + 22 more
- Conditions
- Generalized Anxiety Disorder
- Interventions
- Quetiapine fumarate
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 876 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 58
- States / cities
- Springdale, Arizona • Little Rock, Arkansas • Encino, California + 55 more
- Conditions
- Schizophrenia
- Interventions
- OMS643762, Placebo
- Drug
- Lead sponsor
- Omeros Corporation
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Long Beach, California
- Conditions
- Primary Immunodeficiency
- Interventions
- Immune Globulin Intravenous, Prometic's Immune Globulin Intravenous 10%
- Biological
- Lead sponsor
- Prometic Biotherapeutics, Inc.
- Industry
- Eligibility
- 2 Years to 80 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 13
- States / cities
- Irvine, California • Los Angeles, California • Centennial, Colorado + 10 more
- Conditions
- Menorrhagia
- Interventions
- Aurora Endometrial Ablation, Rollerball Ablation/Resection
- Device
- Lead sponsor
- Minerva Surgical, Inc.
- Industry
- Eligibility
- 25 Years to 50 Years · Female only
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 8
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Newburgh, Indiana + 5 more
- Conditions
- Spinocerebellar Ataxia Type 3
- Interventions
- SLS-005, Placebo
- Drug
- Lead sponsor
- Seelos Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Aurora, Colorado • Tampa, Florida + 4 more
- Conditions
- Primary Hyperoxaluria Type 1, PH1
- Interventions
- YOLT-203, Placebo
- Genetic · Drug
- Lead sponsor
- YolTech Therapeutics Co., Ltd
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Aurora, Colorado • St Louis, Missouri + 1 more